DPP4 and diabetes mellitus: Dipeptidyl peptidase-4 inhibitor administration influences type B intramural hematoma progression in diabetes mellitus patients and leads to a lower aorta-related adverse events rate, aorta-related mortality, and reinterventions than in those who did not receive such drug or those without diabetes mellitus.